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a  b  s  t  r  a  c  t
High-dose  aspirin  has been  reported  to  aggravate  coronary  artery  spasm  (CAS).  However,  it is  unknown
whether  low-dose  aspirin  (LDA;  100  mg)  has  deleterious  impact  on CAS.  We  assessed  the impact  of  LDA  on
CAS induced  by intracoronary  acetylcholine  (ACh)  provocation  test.  A  total  of 2789  consecutive  patients
without  signiﬁcant  coronary  artery  disease  who  underwent  ACh  test  between  November  2004  and  March
2010 were  enrolled.  The  patients  were  divided  into  two groups:  the  aspirin  group  taking  LDA  before  ACh
test  (n =  221)  and  the  no  aspirin  group  not  taking  aspirin  (n  = 2568).  At  baseline,  the  prevalence  of  old
age,  diabetes  mellitus,  hypertension,  and  hyperlipidemia  were  higher  in  the  aspirin  group.  During  the
ACh  test,  the  incidence  of  signiﬁcant  CAS,  ischemic  chest  pain,  as  well  as severe  and  multivessel  spasm
was  higher  in  the  aspirin  group.  The  response  rate to lower  ACh  dose  was  higher in the  aspirin  group.
Multivariate  analysis  showed  that  the  previous  use  of  LDA  was  an  independent  predictor  of  CAS  (adjusted
odds  ratio,  1.6,  95% conﬁdence  interval,  1.0–2.3; p =  0.031).  However,  it is likely  that  the  association  of
LDA  and  CAS  that we have  observed  is  not  causal  but  may  be hypothesis  generating  due  to signiﬁcant
baseline  differences.  Further,  male  gender,  old  age,  lipid-lowering  drugs,  baseline  spasm,  and  myocardial
bridge were  independent  predictors  of CAS.  LDA  was  more  frequently  associated  with  CAS  and  ischemic
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Aspirin is an inhibitor of platelet cyclooxygenase and suppresses
he synthesis of prostaglandin and thromboxane A2. The use of
ow-dose aspirin (LDA, 100 mg)  has increased to prevent heart
ttacks and strokes in high-risk patients [1–3]. But, aspirin has
dverse effects such as gastrointestinal ulcer and bleeding [4] and
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oi:10.1016/j.jjcc.2012.02.007 multivessel  spasm,  suggesting  the  patients  who  have  received  LDA  would
l  therapies  and  close  follow  up.
nese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
igh-dose aspirin had been reported to aggravate coronary artery
pasm (CAS) [5].  However, there are limited data concerning
he impact of the previous use of LDA on CAS. In the present
tudy, we  assessed the clinical and angiographic characteristics of
cetylcholine (ACh) provocation test between previous LDA  users
nd no LDA users and evaluated the adverse impact of LDA on CAS
nduced by ACh test.
aterials and methodstudy population
A  total of 8374 patients underwent coronary angiography
rom November 2004 to August 2010 in Cardiovascular Center of
vier Ltd. All rights reserved.
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orea University Guro Hospital. Among them, 3034 patients (male
4.1%, mean age 54.55 ± 12.43 years) who had typical or atypi-
al chest pain and had been diagnosed by coronary angiography
ith insigniﬁcant coronary artery disease, underwent coronary
ngiography with intracoronary ACh provocation test. The patients
ere excluded if they had one of the following conditions includ-
ng previous percutaneous coronary intervention (PCI), coronary
rtery bypass graft, advanced heart failure (New York Heart Asso-
iation functional class III or IV), and serum creatinine ≥ 3.0 mg/dL,
ecause these conditions can be major causes of adverse cardio-
ascular events and could serve as a bias to CAS. Finally, a total of
789 patients were divided into two groups according to the pre-
ious use of LDA (100 mg)  before ACh provocation test: the aspirin
roup taking LDA (n = 221) and no aspirin group not taking LDA
n = 2568), and clinical and angiographic characteristics during the
Ch provocation test were retrospectively compared between the
wo groups.
cetylcholine provocation test
The ﬁrst investigations for CAS included typical clinical his-
ory, non-invasive stress tests such as treadmill test, ambulatory
lectrocardiogram (ECG) and stress echocardiography, with sub-
equent invasive angiogram performed for conﬁrmation. CAS was
nduced by intracoronary injection of ACh after diagnostic angiog-
aphy. Nitrates, calcium channel blockers (CCB), beta blockers
BB), angiotension-converting enzyme inhibitors (ACEI), and other
asodilators or vasoconstrictors were withheld at least 72 h before
oronary angiography. ACh was injected by incremental doses of
0 (A1), 50 (A2), and 100 (A3) g/min into the left coronary artery
ver a 1 min  period with 5-min intervals to the maximum toler-
ted dose under continuous monitoring of ECG and blood pressure.
ngiography was repeated after each ACh dose. Intracoronary infu-
ion with 0.2 mg  nitroglycerin was given after completing the ACh
rovocation test. Angiography was then performed 2 min  later.
f focal or diffuse signiﬁcant vasoconstriction of coronary arter-
es was induced with any dose of ACh, the ACh infusion was
topped. End systolic images for each segment of the left coro-
ary artery were chosen according to the corresponding points on
he ECG trace (QRS onset or end of T wave) and analyzed using
he proper quantitative laboratory (FD-20, Phillips, Amsterdam,
he Netherlands). The coronary artery diameters were measured
ith quantitative coronary angiography (QCA) before and after
dministration of ACh at the site that showed the greatest changes
ollowing drug administration. Reference diameter was  measured
t the proximal and distal portion of each artery before intracoro-
ary ACh infusion and the mean reference diameter was used
o assess the diameter narrowing. During the coronary angiog-
aphy and ACh provocation test, signiﬁcant CAS was deﬁned as
ocal or diffuse severe transient luminal narrowing (>70%) with
r without chest pain or ischemic ECG change such as ST-T seg-
ent elevation, depression (≥1 mm),  or T wave inversion, and
ormal coronary appearance was deﬁned as less than 20% lumi-
al narrowing on coronary angiogram that was measured with
CA. Myocardial bridge was considered when the characteristic
hasic systolic compression of the coronary artery had a >30%
ecrease in diameter on the angiogram after intracoronary nitro-
lycerin infusion. Multivessel spasm (MVS) was deﬁned as CAS of
2 major epicardial coronary arteries. The presence of baseline
pasm was deﬁned as focal or diffuse narrowing more than 30%
n diameter on the angiogram before the ACh provocation test as
ompared with the ﬁnal angiogram after intracoronary nitroglyc-
rin infusion. Diffuse CAS was deﬁned as signiﬁcant CAS site length
20 mm.
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tudy deﬁnition
Hypertension was deﬁned as either systolic or diastolic eleva-
ion of blood pressure ≥140/90 mmHg  or ongoing antihypertensive
harmacological treatment. Dyslipidemia was  deﬁned as a total
holesterol level ≥200 mg/dL or current treatment with lipid-
owering drugs. Current smoking was  deﬁned as active smoking
ithin the past 12 months. Diabetes mellitus was deﬁned as the
asting blood glucose level ≥126 mg/dL, or use of hypoglycemic
gents or insulin. In the present study, if a patient’s past his-
ory, medical records, present symptoms, or medical examination
esults accorded with one of the following criteria, the patients
ere diagnosed with peripheral arterial disease (PAD): (1) Claudi-
ation symptoms with ankle brachial indices <0.90; (2) Claudica-
ion symptoms with ﬁndings of a signiﬁcant lesion (≥70% diameter
tenosis) in peripheral artery on computed tomographic angiogra-
hy, magnetic resonance angiography, or invasive angiography; (3)
ymptomatic carotid, subclavian arterial disease (≥70% diameter
tenosis) documented by image studies including computed tomo-
raphic angiography, magnetic resonance angiography, or invasive
ngiography. Insigniﬁcant coronary artery disease was  deﬁned as
20% diameter stenosis in coronary arteries documented by image
tudies including computed tomographic angiography, magnetic
esonance angiography, or invasive angiography.
tatistical analysis
All the statistical analyses were performed using SPSS 15.0
SPSS Inc., Chicago, IL, USA). For continuous variables, differ-
nces between two  groups were evaluated by unpaired t-test or
ann-Whitney rank test. For discrete variables, differences were
xpressed as counts and percentages and analyzed with 2 or
isher’s exact test between groups as appropriate. Multivariate
ogistic regression analysis, which included baseline confounding
actors, was used for assessing the independent impact factors. A
wo-tailed p-value of <0.05 was  considered to be statistically sig-
iﬁcant. Data were expressed as mean ± standard deviations.
esults
The baseline clinical characteristics of patients are shown in
able 1. The prevalence of old age, diabetes mellitus, hypertension,
yperlipidemia, PAD, and cerebral vascular disease (CVD) were
igher in the aspirin group. Whereas the level of total cholesterol,
ow-density lipoprotein cholesterol, and high-density lipoprotein
holesterol were lower in the aspirin group, probably due to a
igher rate of using lipid-lowering drugs in the aspirin group than
n the no aspirin group. Before the ACh provocation test, CCB, BB,
nd nitrate were more frequently prescribed in the aspirin group,
nd these results reﬂect the real world medication treatment of
revious LDA users.
The clinical and angiographic parameters of the ACh provoca-
ion test are shown in Table 2.
Before the ACh provocation test, at baseline coronary
ngiogram, the percentage of baseline spasm and myocardial
ridge were similar between the two  groups. During the ACh provo-
ation test, the incidence of ACh-induced CAS and ischemic chest
ain were higher in the aspirin group as compared to no aspirin
roup. The QCA results are shown in Table 2. Before the ACh test,
he baseline epicardial reference diameters after nitroglycerin infu-
ion were similar between the two  groups. After ACh infusion, the
ean % narrowing by QCA was  similar between the two  groups. The
esults for response to the ACh doses and spasm extent are shown
n Table 2. The aspirin group required lower ACh dose (50 g, A2)
nd the incidence of MVS  was higher in the aspirin group.
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Table  1
The baseline clinical characteristics of study groups.
Variables, n (%) Aspirin group (n = 221) No aspirin group (n = 2568) p-value
Male 109 (49.3) 1202 (46.8) 0.483
Age  (years) 60.3 ± 10.5 53.7 ± 12.5 <0.001
Body  mass index (kg/m2) 24.4 ± 3.8 24.2 ± 3.3 0.591
Diabetes mellitus 43(19.5) 290 (11.3) <0.001
Hypertension 147(66.5) 1133 (44.1) <0.001
Hyperlipidemia 52 (23.5) 465 (18.1) 0.048
Smoking 69 (31.2) 734(28.6) 0.439
Cerebral vascular disease 21 (9.5) 56 (2.2) <0.001
Peripheral artery disease 29 (13.1) 114 (4.4) <0.001
Total  cholesterol (mg/dL) 173.9 ± 39.6 183.1 ± 36.6 <0.001
Triglyceride (mg/dL) 136.4 ± 93.6 133.3 ± 95.2 0.674
Low-density lipoprotein cholesterol (mg/dL) 106.9 ± 36.6 116.7 ± 33.2 <0.001
High-density lipoprotein cholesterol (mg/dL) 48.2 ± 13.9 51.8 ± 13.2 <0.001
Lipid-lowering agents 116 (52.5) 825 (32.1) <0.001
Calcium-channel blockers 117 (52.9) 168 (6.5) <0.001
Beta-blockers 73 (33.0) 77 (3.0) <0.001
Angiotensin-converting enzyme inhibitors 24 (10.9) 23 (0.9) <0.001
Nitrate  127 (57.5) 534 (20.8) <0.001
Table 2
The clinical and angiographic parameters during ACh provocation test.
Variables, n (%) Aspirin group (n = 221) No aspirin group (n = 2568) p-value
Reference diameter after NTG infusion (mm)  2.5 ± 0.6 2.4 ± 0.6 0.072
Diameter narrowing after ACh infusion (mm) 0.7 ± 0.4 0.7 ± 0.4 0.923
Diameter narrowing after ACh infusion (%) 70.9 ± 14.3 69.9 ± 13.4 0.403
Baseline spasm before the test 64 (29.0) 694 (27.0) 0.581
ACh-induced coronary artery spasm 146 (66.1) 1440 (56.0) 0.010
Maximal tolerable dose of ACh
A1  (20 g) 8 (3.6) 89 (3.5) 1.000
A2  (50 g) 61 (27.6) 490 (19.1) 0.003
A3  (100 g) 77 (34.8) 861 (33.5) 0.711
Spasm  extent
Diffuse 125 (56.5) 1188 (46.3) 0.183
Focal  96 (43.5) 1380 (53.7) 0.183
Multivessel 67 (30.3) 490 (19.1) <0.001
Myocardial bridge 50 (22.6) 539 (21.0) 0.609
Ischemic electrocardiogram change during the test 6 (2.8) 60 (2.4) 0.429
Chest  pain during the test 117 (52.9) 1162 (45.2) 0.029
ACh, acetylcholine; NTG, nitroglycerin.
Table 3
Multivariable logistic analysis of the predictors of acetylcholine-induced coronary artery spasm.
Variables Unadjusted OR p-value 95% CI Adjusted OR p-value 95% CI
Old age (>55 years) 1.4 <0.001 1.2–1.6 1.5 <0.001 1.3–1.9
Male  1.5 <0.001 1.1–1.5 1.5 <0.001 1.3–1.9
Hypertension 1.0 0.992 0.8–1.2
Hyperlipidemia 1.2 0.183 1.1–2.4
Diabetes mellitus 1.3 0.131 0.9–1.7
Smoking 1.4 0.001 1.1–1.7
Peripheral vascular disease 1.7 0.007 1.2–2.6
Cerebral vascular disease 1.4 0.255 0.7–2.6
Low-dose (100 mg)  aspirin 1.9 <0.001 1.3–2.8 1.6 0.034 1.0–2.4
ACE  inhibitors 1.5 0.380 0.6–3.4
Lipid-lowering agent 1.6 <0.001 1.4–1.9 1.3 0.006 1.1–1.6
Baseline spasm 1.8 <0.001 1.5–2.2 1.7 <0.001 1.4–2.1
O
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DMyocardial bridge 2.8 <0.001 
R, odds ratio; CI, conﬁdence interval; ACE, angiotensin-converting enzyme.
We  evaluated independent predictors for ACh-induced CAS
y adjusting possible confounding factors including age, gen-
er, hypertension, diabetes mellitus, hyperlipidemia, current
moking, CVD, PAD, medication history including the previ-
us use of LDA and ACEI, baseline spasm, and myocardial
ridge. The results are listed in Table 3. Multivariate analy-
is showed that the previous use of LDA was an independent
redictor of CAS induced by ACh test (adjusted odds ratio,
.6, 95% conﬁdence interval, 1.0–2.3; p = 0.031). Further, male,
w
a2.2–3.7 2.8 <0.001 2.1–3.7
ld age, lipid-lowering drugs, baseline spasm, and myocar-
ial bridge were also independent predictors of ACh-induced
AS.
iscussionThe main ﬁnding of this study is that the patients taking LDA
as more frequently associated with ischemic symptoms, CAS,
s well as severe and MVS, suggesting this particular subset of
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atients would require more intensive medical therapies and close
ollow up.
However, in this study, the prevalence of risk factors for
therosclerosis including old age, diabetes mellitus, hypertension,
nd hyperlipidemia were higher in the aspirin group. The previous
se of LDA was associated with a higher incidence of ACh-induced
AS, frequent ischemic symptoms, MVS, and showed vulnerable
esponse to lower doses of ACh provocation test as compared to
he non LDA group. Therefore, it is likely that the association of LDA
nd CAS that we  have observed is not causal but may  be hypothe-
is generating due to signiﬁcant baseline differences between the
wo groups. Nevertheless, this study shows that the patients taking
he LDA have a higher number of risk factors for atherosclerosis in
he real world and would be associated with a higher incidence of
linically signiﬁcant CAS, frequent ischemic symptoms, MVS, and
howed vulnerable response to lower ACh dose. Thus, patients who
ave received LDA before ACh test would require special atten-
ion during ACh provocation test, more intensive medical therapies
ncluding antianginal agents, and close clinical follow up. Since the
rst description of variant angina by Prinzmetal et al. in 1959 [6],
he epidemiology of CAS had been studied extensively. Recently,
he endothelial dysfunction induced by abnormalities of endothe-
ial nitric oxide synthase (eNOS) and enhanced contractility of
ascular smooth muscle in coronary artery have been considered
ajor mechanisms of CAS [7].
Aspirin is known to suppress the synthesis of prostaglandin and
hromboxane A2 by blocking cyclooxygenase [8].  Prostaglandins
nd thromboxane A2 play a role in modulation of coronary
rtery. Prostaglandins induce vasodilatation of coronary artery and
hromboxane A2 invoke vasoconstriction and platelet aggregation
9]. Therefore, unbalance in the levels of thromboxane A2 and
rostaglandins would cause angina attacks in patients with coro-
ary artery disease. Numano et al. reported that the patients with
ariant angina had a lower level of 6-keto prostacycline with sta-
istically signiﬁcant difference as compared to a control group [10].
ut, the level of thromboxane B2 was similar between the two
roups. This study suggested that the low level of prostacycline may
e more of a contributing factor to CAS compared to high level of
hromboxane B2. Miwa et al. reported that large amounts of aspirin
4.0 mg/day) aggravate the occurrence of CAS by the action of block-
ng the endothelial prostaglandin synthesis of the coronary artery
5].  The use of LDA has widely increased to prevent heart attacks
nd strokes in high-risk patients [1–3]. However, the relationship
etween LDA and CAS was rarely reported. Robertson et al. reported
hat LDA has no effect on the frequency and duration of CAS [11].
ut in the present study, the previous use of LDA was  an indepen-
ent predictor of CAS induced by intracoronary ACh provocation
est. The previous LDA users had higher incidence of ACh-induced
AS, severe spasm extent such as MVS, and more frequent ischemic
hest pain as compared to no LDA users.
In the present study, the previous LDA users had higher preva-
ence of conventional risk factors of atherosclerosis including
iabetes mellitus, hypertension, hyperlipidemia, PAD, and CVD
han no aspirin users, and this result suggests that in the real world,
he previous LDA users have high risk factors of atherosclerosis and
ave the chance of much more severe endothelial dysfunction than
xpected. Thus, the incidence and severity of CAS, the degree of
pasm extent, and clinical symptoms during the test were more
requent in the LDA users than no aspirin users.
In the present study, old age and myocardial bridge were also
redictors of CAS. Old age has been reported to be a signiﬁcant
isk factor of endothelial dysfunction and induce signiﬁcant CAS
uring ACh provocation test. In our previous study, myocardial
ridge had been reported to be an independent predictor of focal
pasm [12]. Myocardial bridge invokes longitudinal compression
t
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elaxation stress of coronary artery which induces the endothelial
ysfunction and may  increase the risk of CAS.
In this study, the presence of baseline spasm before ACh test
as an independent predictor of CAS. However, the incidence of
aseline spasm was similar between the LDA and no LDA groups.
urther, multivariate analysis showed that the LDA was not an inde-
endent predictor of baseline spasm (adjusted odds ratio = 1.015,
5% conﬁdence interval, 0.7–1.5; p = 0.943). These results showed
hat baseline spasm was  not associated with LDA and LDA itself did
ot promote baseline spasm.
Lipid-lowering drugs have been shown to improve endothelial
unction, and would be thus expected to reduce the likelihood of
AS. However, in the present study, the use of lipid-lowering drugs
as an independent predictor of ACh-induced CAS. The most rea-
onable explanation for this ﬁnding is that the lipid-lowering drugs
ere more commonly prescribed for patients with atherosclerosis,
nd it is more likely to be associated with higher incidence of risk
actors requiring lipid-lowering drugs in the LDA group rather than
 causal relationship.
In the present study, the previous LDA users were more fre-
uently prescribed CCB and nitrate as compared to no aspirin users.
evertheless, the previous LDA users had higher incidence of CAS
uring ACh provocation test as compared with non aspirin users.
ccording to these results, we assumed that in the real world, the
revious LDA users have much more chances of severe endothe-
ial dysfunction than expected and would require more aggressive
edical treatment using antianginal drugs than until now [13,14].
There are several limitations of this study. In this study, we used
 more safe deﬁnition of signiﬁcant CAS as compared to other previ-
us studies related to ACh provocation test. We  deﬁned signiﬁcant
AS as focal or diffuse severe transient luminal narrowing (>70%)
n order to prevent the situation of hemodynamic collapse due to
evere and intractable CAS. In an earlier period of our registry, we
xperienced some intractable CAS patients who did not experience
uick relief by intracoronary nitroglycerin injection. Few patients
xperienced cardiogenic shock and cardiac arrest during the ACh
rovocation test. Our diagnostic criteria were established to ensure
he safety of the patients. Our criteria are just for the clinical deci-
ion of whether we  should treat or not. Thus, in this study, when we
bserve angiographically signiﬁcant narrowing (>70%) regardless
f the patient’s severe chest pain or ST-T change in ECG during ACh
rovocation test, intracoronary nitroglycerin was injected instantly
or the safety of the patients. Therefore, the incidence of ischemic
hest pain and ECG change was  relatively low. This policy was  for
he safety of patients and it did not negatively impact on our deci-
ion whether to treat or not. If we had ignored the patients’ chest
ain or severe narrowing, did not inject nitroglycerin promptly, and
ncrease ACh dose to A3 (100 g/min), the incidence of ischemic
hest pain and ECG change would be drastically increased.
The data for this study are the all comer data of Korean popu-
ation and are not selectively enrolled data. These results are the
bservational ﬁndings in a real world, all comers-based registry
nd can be regarded as valuable characteristics found in the Korean
opulation.
In this study, ACh spasm provocation test was  performed only
n the left coronary artery, not to both the left and right coronary
rteries. In Asian countries including Korea, Japan, and China, the
iagnostic coronary angiography is now largely being performed
y transradial approach instead of transfemoral approach for its
afety and shorter stay at the hospital. In this study, most patients
n our center underwent coronary angiography and ACh provoca-
ion test through 4Fr radial approach for the convenience of study.
f we perform the ACh provocation test in dominant left circum-
ex artery or directly into the right coronary artery, we will need
he temporary pacemaker from the femoral vein due to advanced
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oronary atrioventricular block due to the ACh action. In that case,
he patients need additional vascular access in the groin, will cost
 lot for the temporary pacing, and further longer hospital stay.
herefore, for the safety of patients and convenience of study, it
s difﬁcult to perform both femoral and radial approach, and we
erformed the provocation test in left coronary artery alone. Fur-
her, our preliminary study data showed that the ACh provocation
est into left coronary artery alone gives us reliable and deﬁnite
nformation to decide the diagnosis and guide for medical therapy.
The data of this study were analyzed retrospectively and com-
rise the prospective real world spasm registry for all comers in
he Korean population. Therefore, the result of this study was a
ypothesis-generating conclusion and a larger prospective ran-
omized study will be needed for deﬁnite conclusion regarding the
mpact of LDA on ACh provocation test results in the future.
The focus of this study is regarding the observation of the clini-
al and angiographic parameters during ACh provocation test, not
he major clinical events throughout the longer clinical follow up.
ecause of the characteristics of the study population without PCI
ho are medically followed at outpatient department with rela-
ively shorter-term follow up, the extensive information regarding
linical outcomes in the study population is not currently available.
he clinical outcome information of CAS patients will be the future
hallenges of our study. However, at this moment, we  focused on
he index clinical and procedural parameters at the time of ACh
rovocation test.
onclusion
The use of LDA has increased to prevent heart attacks and
trokes in high-risk patients. However, it was not well known
hether the previous use of LDA has an adverse impact on CAS.
espite the non-randomized nature and signiﬁcant baseline dif-
erences, the previous LDA users were associated with higher
ncidence of ACh-induced CAS, more ischemic chest pain, MVS, and
equired lower ACh dose than no aspirin users, suggesting more
ggressive medical treatment with special care would be needed.
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